Advancing the detection of heart diseases

We connect clinicians and their patients in following heart health through smartphones.

Soon available in the USA

CardioSignal develops remote care solutions so that at-risk patients would have better access to cardiovascular care– wherever they are

✔ Heart assessment for telehealth

✔ Population health initiatives

✔ Remote patient monitoring

✔ Elderly & remote care

Cardiac biomarkers that connects clinicians to their patients in order to follow their heart health.

Through smartphones, patients have access to an application that makes daily heart checkups effortless – in customer surveys, over 90% of users in the 60-plus age group describe our technology easy to use.

For professionals, we enable tools for improved point-of-care diagnostics and a way to provide care at a distance for at-risk patients in remote and rural areas.

  • CardioSignal is developing digital cardiac biomarkers for detecting signs of major heart diseases. The gyrocardiography technology can generate clinically validated biomarkers for atrial fibrillation, heart failure and valve diseases.

  • With a 1-minute measurement, CardioSignal can collect and analyze vital signs: heart rate, heart rate variability (HRV) and respiratory rate.

  • Using smartphones in remote care models allows unlimited scalability. Onboarding to the application can be done by the patients themselves, in a matter of minutes.

Collaborations and Clinical Studies

We develop novel solutions for the detection of heart diseases with digital cardiac biomarkers. The gyrocardiography method utilizes motion sensors to non-invasively measure chest movements and determine cardiac motion and function.

We are developing digital cardiac biomarkers for:

  • Heart Failure

  • Coronary Artery Disease

  • Valve Disease

  • Pulmonary Hypertension

We are actively partnering with academic institutions and biopharma companies to search for new ways to improve patient outcomes in heart disease. Contact CardioSignal Inc President Tero-Pekka Alastalo (tpa@cardiosignal.com) for further information.